Santhera Pharmaceuticals AG

Drug discovery through chemical microarray platform

Santhera was formed in 2004 when Graffinity Pharmaceuticals AG and Myocontract AG merged, joining small molecule drug discovery and development expertise and expertise in neuromuscular diseases.

In January 2006, the company announced the completion of the management buyout of its Graffinity technology business unit.

Klaus Schollmeier (CEO)
Barbara A. Heller (CFO)
Thomas Meier (CSO)
Helmut Kessmann (CBO)

Michael Lytton (Chairman)
Peter Wolf (Vice Chairman)
Mark Clement
Rudolf Gygax
Georg Nebgen
Timothy Rink
Bernd R. Seizinger

Hammerstrasse 47
4410 Liestal
Switzerland
Phone: +41-61-906-8950
Fax: +41-61-906-8951